Description
Nonalcoholic Steatohepatitis (NASH) is a disease that results when fat accumulates in the liver and eventually causes inflammation and scarring called fibrosis. The purpose of this study is to test whether an experimental drug, Elafibranor, is safe and effective in treating advanced scarring of the liver due to NASH.
Overview
Eligible patients will be randomly assigned to take study drug or placebo. Neither you nor the researchers will know which you are taking. Study visits occur approximately once every 3 months for the first 18th months, then every 24 weeks after that. At these visits researchers will ask you questions about your health, medications you are taking, and if you are having any problems with your health.
What we're hoping for
To find out if the study drug, Elafibranor, is safe and effective for treating patients with the liver disease nonalcoholic steatohepatitis (NASH) and fibrosis.
Additional Information
ClinicalTrials.gov Identifier: NCT02704403